Trial Profile
An Open Label Single Arm Study to Investigate the Safety and Efficacy of Multiple Administrations of NI-0801, a Fully Human Anti-CXCL10 Monoclonal Antibody in PBC Patients With an Incomplete Response to Ursodeoxycholic Acid
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs NI 0801 (Primary)
- Indications Biliary cirrhosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PIANO
- Sponsors Light Chain Bioscience
- 28 Oct 2014 New trial record